Baird analyst Brian Skorney reiterated an Outperform rating and $130.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst comments "Incrementally ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Stifel on Mirum Pharmaceuticals (MIRM): 'We think the opportunity here remains under-appreciate'October 12, 2026 9:30 AM RBC Capital on Mirum (MIRM): 'we could see MIRM shares up 5–10% on the EXPAND news'October 12, 2026 9:30 AM Mirum's maralixibat meets primary endpoint in rare liver disease trialOctober 12, 2026 8:00 AM Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver DiseasesOctober 12, 2026 8:00 AM Mirum Pharmaceuticals to release Phase 3 maralixibat study resultsOctober 11, 2026 5:00 PM Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver DiseasesOctober 11, 2026 5:00 PM Mirum Pharmaceuticals (MIRM) PT Raised to $155 at RBC CapitalOctober 8, 2026 8:27 AM